Corrigendum to Prophylactic antibiotics in patients with alcohol-associated hepatitis receiving steroids: A systematic review and meta-analysis

IF 6 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Liver International Pub Date : 2024-10-28 DOI:10.1111/liv.16110

{"title":"Corrigendum to Prophylactic antibiotics in patients with alcohol-associated hepatitis receiving steroids: A systematic review and meta-analysis","authors":"","doi":"10.1111/liv.16110","DOIUrl":null,"url":null,"abstract":"Quek JWE, Loo JH, Jaroenlapnopparat A, et al. Prophylactic antibiotics in patients with alcohol-associated hepatitis receiving steroids: A systematic review and meta-analysis. Liver Int. 2024;44(9):2469-2476. doi:10.1111/liv.16014In the article by Quek et al. [1], an error appeared in Table 1 where the included studies were wrongly referenced. The revised Table 1 with the correct references is shown here:We apologize for the error.\n REFERENCES\n 1. Quek JWE, Loo JH, Jaroenlapnopparat A, et al. Prophylactic antibiotics in patients with alcohol-associated hepatitis receiving steroids: a systematic review and meta-analysis. Liver Int. 2024;44(9):2469-2476. doi:10.1111/liv.1601434. Louvet A, Labreuche J, Dao T, et al. Effect of prophylactic antibiotics on mortality in severe alcohol-related hepatitis: a randomized clinical trial. JAMA. 2023;329(18):1558-1566. doi:10.1001/jama.2023.490236. Kimer N, Meldgaard M, Hamberg O, et al. The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: a randomized clinical trial. PLoS ONE. 2022;17(3):e0264278. doi:10.1371/journal.pone.026427833. Kulkarni AV, Tirumalle S, Premkumar M, et al. Primary norfloxacin prophylaxis for APASL-defined acute-on-chronic liver failure: a placebo-controlled double-blind randomized trial. Am J Gastroenterol. 2022;117(4):607-616. doi:10.14309/ajg.000000000000161137. Jiménez C, Ventura-Cots M, Sala M, et al. Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: a pilot study (RIFA-AH). Liver Int. 2022;42(5):1109-1120. doi:10.1111/liv.1520722. Støy S, Laursen TL, Eriksen LL, Grønbæk H, Vilstrup H, Sandahl TD. No effect in alcoholic hepatitis of gut-selective, broad-spectrum antibiotics on bacterial translocation or hepatic and systemic inflammation. Clin Transl Gastroenterol. 2021;12(2):e00306. doi:10.14309/ctg.000000000000030638. Popescu A, Voiculescu M. Improved survival in patients with advanced alcoholic hepatitis (AAH) with a combined treatment associating a non-absorbable antibiotic rifaximin to corticoids plus ursodeoxycholic acid (UDCA). J Hepatol. 2009;50:S369. doi:10.1016/S0168-8278(09)61022-9","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"44 12","pages":"3293-3294"},"PeriodicalIF":6.0000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.16110","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver International","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/liv.16110","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Quek JWE, Loo JH, Jaroenlapnopparat A, et al. Prophylactic antibiotics in patients with alcohol-associated hepatitis receiving steroids: A systematic review and meta-analysis. Liver Int. 2024;44(9):2469-2476. doi:10.1111/liv.16014

In the article by Quek et al. [1], an error appeared in Table 1 where the included studies were wrongly referenced. The revised Table 1 with the correct references is shown here:

We apologize for the error.

REFERENCES

1. Quek JWE, Loo JH, Jaroenlapnopparat A, et al. Prophylactic antibiotics in patients with alcohol-associated hepatitis receiving steroids: a systematic review and meta-analysis. Liver Int. 2024;44(9):2469-2476. doi:10.1111/liv.16014

34. Louvet A, Labreuche J, Dao T, et al. Effect of prophylactic antibiotics on mortality in severe alcohol-related hepatitis: a randomized clinical trial. JAMA. 2023;329(18):1558-1566. doi:10.1001/jama.2023.4902

36. Kimer N, Meldgaard M, Hamberg O, et al. The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: a randomized clinical trial. PLoS ONE. 2022;17(3):e0264278. doi:10.1371/journal.pone.0264278

33. Kulkarni AV, Tirumalle S, Premkumar M, et al. Primary norfloxacin prophylaxis for APASL-defined acute-on-chronic liver failure: a placebo-controlled double-blind randomized trial. Am J Gastroenterol. 2022;117(4):607-616. doi:10.14309/ajg.0000000000001611

37. Jiménez C, Ventura-Cots M, Sala M, et al. Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: a pilot study (RIFA-AH). Liver Int. 2022;42(5):1109-1120. doi:10.1111/liv.15207

22. Støy S, Laursen TL, Eriksen LL, Grønbæk H, Vilstrup H, Sandahl TD. No effect in alcoholic hepatitis of gut-selective, broad-spectrum antibiotics on bacterial translocation or hepatic and systemic inflammation. Clin Transl Gastroenterol. 2021;12(2):e00306. doi:10.14309/ctg.0000000000000306

38. Popescu A, Voiculescu M. Improved survival in patients with advanced alcoholic hepatitis (AAH) with a combined treatment associating a non-absorbable antibiotic rifaximin to corticoids plus ursodeoxycholic acid (UDCA). J Hepatol. 2009;50:S369. doi:10.1016/S0168-8278(09)61022-9

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

对接受类固醇治疗的酒精相关性肝炎患者使用预防性抗生素的更正：系统回顾和荟萃分析。

Quek JWE、Loo JH、Jaroenlapnopparat A 等.接受类固醇治疗的酒精相关性肝炎患者的预防性抗生素：系统综述与荟萃分析》。Liver Int. 2024;44(9):2469-2476. Doi:10.1111/liv.16014在Quek等人的文章[1]中，表1出现了错误，其中纳入的研究参考文献有误。修订后的表 1 包含了正确的参考文献：我们对这一错误表示歉意。参考文献 1.Quek JWE, Loo JH, Jaroenlapnopparat A, et al. 接受类固醇治疗的酒精相关性肝炎患者的预防性抗生素：系统回顾和荟萃分析。Liver Int. 2024;44(9):2469-2476. doi:10.1111/liv.1601434.Louvet A, Labreuche J, Dao T, et al. 预防性抗生素对严重酒精相关性肝炎死亡率的影响：随机临床试验。JAMA.2023;329(18):1558-1566. doi:10.1001/jama.2023.490236.Kimer N, Meldgaard M, Hamberg O, et al. 利福昔明对酒精性肝炎炎症和代谢的影响：随机临床试验。PLoS ONE.2022;17(3):e0264278. doi:10.1371/journal.pone.026427833.Kulkarni AV, Tirumalle S, Premkumar M, et al. Primary norfloxacin prophylaxis for APASL-defined acute-on-chronic liver failure: a placebo-controlled double-blind randomized trial.Am J Gastroenterol.2022;117(4):607-616. doi:10.14309/ajg.000000000000161137.Jiménez C, Ventura-Cots M, Sala M, et al. 利福昔明对酒精性肝炎感染、急性-慢性肝功能衰竭和死亡率的影响：一项试点研究（RIFA-AH）。2022；42（5）：1109-1120。DOI：10.1111/LIV.1520722。Støy S, Laursen TL, Eriksen LL, Grønbæk H, Vilstrup H, Sandahl TD.肠道选择性广谱抗生素对酒精性肝炎的细菌转运或肝脏和全身炎症无影响。Clin Transl Gastroenterol.2021;12(2):e00306. doi:10.14309/ctg.000000000000030638.Popescu A, Voiculescu M. 通过将非吸收性抗生素利福昔明与皮质激素加熊去氧胆酸（UDCA）联合治疗改善晚期酒精性肝炎（AAH）患者的生存率。J Hepatol.2009;50:S369. doi:10.1016/S0168-8278(09)61022-9

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Liver International 医学-胃肠肝病学

CiteScore

13.90

自引率

4.50%

发文量

348

审稿时长

2 months

期刊介绍： Liver International promotes all aspects of the science of hepatology from basic research to applied clinical studies. Providing an international forum for the publication of high-quality original research in hepatology, it is an essential resource for everyone working on normal and abnormal structure and function in the liver and its constituent cells, including clinicians and basic scientists involved in the multi-disciplinary field of hepatology. The journal welcomes articles from all fields of hepatology, which may be published as original articles, brief definitive reports, reviews, mini-reviews, images in hepatology and letters to the Editor.